Eli Lilly and Company’s Stock Price Soars to $785.41, Marking a Strong 2.45% Uptick in Performance

Eli Lilly and Company (LLY)

785.41 USD +18.81 (+2.45%) Volume: 4.14M

Eli Lilly and Company’s stock price currently stands at 785.41 USD, marking a promising increase of +2.45% this trading session. With a solid trading volume of 4.14M and a year-to-date percentage change of +1.74%, LLY’s stock performance continues to show positive momentum, making it a significant player in the pharmaceutical sector.

Latest developments on Eli Lilly and Company

Eli Lilly & Company has been making headlines recently, with the confirmation of the date and conference call for their fourth-quarter 2024 financial results and 2025 financial guidance announcement. The pharmaceutical giant’s stock price has been on the move, with shares falling after GLP-1 sales missed expectations and dipping further on Novo Nordisk’s rival drug data. Despite these setbacks, Eli Lilly’s stock price has seen some positive movements, with shares up 2.6% and an increase of 0.5%. Analysts at BofA Securities have reiterated a buy rating on Eli Lilly, with a target price of $997. With news of potential FDA approval for a weight-loss pill and new partnerships in the pipeline, investors are keeping a close eye on Eli Lilly’s stock performance.

A look at Eli Lilly and Company Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Eli Lilly & Company has a mixed long-term outlook. The company scores well in Growth and Dividend, indicating potential for future expansion and consistent dividend payouts. However, its Value and Resilience scores are lower, suggesting that the company may not be as financially stable or undervalued compared to its peers. The Momentum score falls in the middle, reflecting a moderate level of market activity and investor interest in the company.

Eli Lilly & Company is a pharmaceutical company that focuses on discovering, developing, manufacturing, and selling products for both humans and animals. Its product portfolio includes a wide range of pharmaceuticals, such as neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology treatments, and animal health products. With a strong emphasis on research and development, the company is positioned for growth in the pharmaceutical industry, supported by its consistent dividend payouts to investors.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma